Saurashtra News

Trigeminal Neuralgia Market to Exhibit Moderate Growth Rate till 2032, Investigates DelveInsight | Key Companies – Novartis, Biogen, Biohaven Pharmaceuticals, and Others

 Breaking News
  • No posts were found

Trigeminal Neuralgia Market to Exhibit Moderate Growth Rate till 2032, Investigates DelveInsight | Key Companies – Novartis, Biogen, Biohaven Pharmaceuticals, and Others

May 02
22:32 2022
Trigeminal Neuralgia Market to Exhibit Moderate Growth Rate till 2032, Investigates DelveInsight | Key Companies - Novartis, Biogen, Biohaven Pharmaceuticals, and Others
Delveinsight Business Research LLP
DelveInsight’s “Trigeminal Neuralgia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Trigeminal Neuralgia Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Trigeminal Neuralgia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Trigeminal Neuralgia: An Overview

Trigeminal Neuralgia (TN), also known as tic douloureux, is a chronic pain condition that affects the trigeminal or fifth cranial nerve, one of the most widely distributed nerves in the head. TN is a form of neuropathic pain (pain associated with nerve injury or nerve lesion). Trigeminal neuralgia is categorized into two types: primary (idiopathic) and secondary.

TN is associated with a variety of conditions. TN can be caused by a blood vessel pressing on the trigeminal nerve as it exits the brain stem; this compression causes the wearing away or damage to the protective coating around the nerve (the myelin sheath).

TN occurs most often in people over age 50, although it can occur at any age, including infancy. The possibility of TN being caused by multiple sclerosis increases when it occurs in young adults. The incidence of new cases is approximately 12 per 100,000 people per year; the disorder is more common in women than in men.

Trigeminal Neuralgia Market Key Facts

  • As per the National Organization for Rare Disorders (NORD), trigeminal neuralgia affects females slightly more often than males. Although the exact incidence is unknown, approximately 10,000–15,000 new cases occur each year in the United States.

  • A study conducted by Obermann et al. in Germany titled “Treatment options in trigeminal neuralgia,” indicated that the incidence of trigeminal neuralgia (TN) is 4.3 per 100,000 persons per year, with a slightly higher incidence for women (5.9 per 100,000) as compared to men (3.4 per 100,000). There is a lack of certainty regarding the etiology and pathophysiology of TN. 

Trigeminal Neuralgia Market

Trigeminal Neuralgia market size is anticipated to increase during the study period owing to the rise in the number of incident cases in the 7MM. The expected launch of the upcoming therapies will also fuel the growth of the market.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Trigeminal Neuralgia market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Trigeminal Neuralgia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Trigeminal Neuralgia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Trigeminal Neuralgia Epidemiology Segmentation –

  • Incident Cases of Trigeminal Neuralgia (TN)

  • Gender‐Specific Cases of Trigeminal Neuralgia (TN)

  • Diagnosed and Treatable Cases of Trigeminal Neuralgia

Trigeminal Neuralgia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Trigeminal Neuralgia market or expected to get launched during the study period. The analysis covers Trigeminal Neuralgia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Trigeminal Neuralgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market

Trigeminal Neuralgia Therapeutics Analysis

The Trigeminal Neuralgia (TN) market dynamic is expected to change due to the improvement in the diagnosis, incremental healthcare expenditure across the world, and the expected launch of emerging therapies during the forecast period.

Companies all over the globe are persistently working toward the development of new treatment therapies. The launch of the emerging therapies is expected to change the Trigeminal Neuralgia treatment scenario in the coming years.

Some of the Companies in the Trigeminal Neuralgia Market Includes:

  • Novartis

  • Biogen

  • Biohaven Pharmaceuticals

And many others.

Trigeminal Neuralgia Therapies covered in the report include:

  • Vixotrigine (BIIB074)

  • Rimegepant

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies – 
https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Trigeminal Neuralgia Competitive Intelligence Analysis

4. Trigeminal Neuralgia Market Overview at a Glance

5. Trigeminal Neuralgia Disease Background and Overview

6. Trigeminal Neuralgia Patient Journey

7. Trigeminal Neuralgia Epidemiology and Patient Population

8. Trigeminal Neuralgia Treatment Algorithm, Current Treatment, and Medical Practices

9. Trigeminal Neuralgia Unmet Needs

10. Key Endpoints of Trigeminal Neuralgia Treatment

11. Trigeminal Neuralgia Marketed Products

12. Trigeminal Neuralgia Emerging Therapies

13. Trigeminal Neuralgia Seven Major Market Analysis

14. Attribute Analysis

15. Trigeminal Neuralgia Market Outlook (7 major markets)

16. Trigeminal Neuralgia Access and Reimbursement Overview

17. KOL Views on the Trigeminal Neuralgia Market.

18. Trigeminal Neuralgia Market Drivers

19. Trigeminal Neuralgia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Gene And Cell Therapies In Rare Disorder Market

DelveInsight’s “Gene And Cell Therapies In Rare Disorder Market” reports deliver an in-depth understanding of the historical and forecasted epidemiology, the pipeline insight as well as the market size and shares analysis in the seven major markets (7MM). The report also covers emerging therapies, current treatment practices, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles